Connect with us

Stocks

Are Investors Wary Of Weatherford International plc (WFT)?

Published

on

Stock of Weatherford International plc (WFT) opened today at $3.24 and are currently trading at $3.54 x 900. More than 37,330,218 shares have exchanged hands compared to an average daily volume of 17,626,846 shares. At the current pps, the market capitalization stands at 3.43B. Analyst are currently predicting a target of $5.89 for Weatherford International plc (WFT).

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. Weatherford International plc (WFT) currently has a Beta value of 2.58. Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent.

Next, let’s take a look at Weatherford International plc (WFT) current P/E ratio. Weatherford International plc (WFT) currently has a PE ratio of 1.87. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at Weatherford International plc (WFT) beta and P/E ratio, the EPS cannot be ignored. Weatherford International plc (WFT) EPS for the trailing twelve months was -3.09. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. Weatherford International plc (WFT) is estimated to release its next earnings report on Oct 24, 2017 – Oct 30, 2017. It would be interesting to see how the earnings fair out considering the recent developments.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stocks

CA, Inc. (CA) Could Be In For A Major Breakout

Published

on

Stock of CA, Inc. (CA) opened at $32.26 and last traded at $32.12 x 800. More than 693,693 shares exchanged hands compared to an average daily volume of 1,677,896 shares. At the current pps, the market capitalization stands at 13.41B.

TriNet Group, Inc. (NYSE: TNET), a leading provider of comprehensive HR solutions, today announced that Richard Beckert has joined TriNet as senior vice president of finance. Beckert will be appointed as chief financial officer immediately following…

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. CA, Inc. (CA) currently has a Beta value of 1.04 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at CA, Inc current P/E ratio. CA, Inc. (CA) currently has a PE ratio of 17.80. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at CA, Inc beta and P/E ratio, the EPS cannot be ignored. CA, Inc EPS for the trailing twelve months was 1.80. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. CA, Inc is estimated to release its next earnings report on 3 / 2018 (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

CA, Inc. (CA) has received an average target price from analysts of $32.95 amounting to a recommendation rating of Hold. That comes from 17 different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of 13.19. To give a sense of trend, the same data point on the estimate for next year is currently sitting at 12.68 times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of 14.00. That shift to 14.00 heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

Stocks

Why BioMarin Pharmaceutical Inc. (BMRN) could blow up your portfolio

Published

on

Stock of BioMarin Pharmaceutical Inc. (BMRN) opened at $81.82 and last traded at $81.32 x 200. More than 539,968 shares exchanged hands compared to an average daily volume of 1,351,136 shares. At the current pps, the market capitalization stands at 14.27B.

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. BioMarin Pharmaceutical Inc. (BMRN) currently has a Beta value of 1.42 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at BioMarin Pharmaceutical Inc current P/E ratio. BioMarin Pharmaceutical Inc. (BMRN) currently has a PE ratio of N/A. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at BioMarin Pharmaceutical Inc beta and P/E ratio, the EPS cannot be ignored. BioMarin Pharmaceutical Inc EPS for the trailing twelve months was -1.07. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. BioMarin Pharmaceutical Inc is estimated to release its next earnings report on N/A (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

BioMarin Pharmaceutical Inc. (BMRN) has received an average target price from analysts of ${{marketwatch_AverageTargetPrice}} amounting to a recommendation rating of {{marketwatch_AverageRecommendation}}. That comes from {{marketwatch_NumberofRatings}} different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of {{marketwatch_MedianPEonCYEstimate}}. To give a sense of trend, the same data point on the estimate for next year is currently sitting at {{marketwatch_MedianPEonNextFYEstimate}} times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of {{marketwatch_NoofEstimates_this_quarter}}. That shift to {{marketwatch_NoofEstimates_next_quarter}} heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

Stocks

Biogen Inc. (BIIB) finding value in an unloved sector

Published

on

Stock of Biogen Inc. (BIIB) opened at $309.69 and last traded at $312.51 x 200. More than 463,536 shares exchanged hands compared to an average daily volume of 1,353,516 shares. At the current pps, the market capitalization stands at 65.71B.

Fundamentals you simply cannot ignore

Investors try to use stocks with high beta values to quickly recoup their investments after sharp market losses. Biogen Inc. (BIIB) currently has a Beta value of 1.37 . Beta is a measurement of a stock’s price fluctuations, which is often called volatility and is used by investors to gauge how quickly a stock’s price will rise or fall. A stock with a beta of greater than 1.0 is riskier and has greater price fluctuations, while stocks with beta values of less than 1.0 are steadier and generally larger companies. Beta is often measured against the S&P; 500 index. An S&P; 500 stock with a beta of 2.0 produced a 20 percent increase in returns during a period of time when the S&P; 500 Index grew only 10 percent. This same measurement also means the stock would lose 20 percent when the market dropped by only 10 percent. Next, let’s take a look at Biogen Inc current P/E ratio. Biogen Inc. (BIIB) currently has a PE ratio of 20.39. PE ratio is an important parameter to look at when trading a stock mostly because it is easy to calculate. There are a couple of ways to calculate PE ratio either by dividing share price by earnings per share or dividing the market cap by net income. It is important to note that the earnings are usually taken from the trailing twelve months (TTM). Nevertheless, P/E tells us how much an investor is willing to pay for $1 of a company’s earnings. The long-term average P/E is around 15, so on average, investors are willing to pay $15 for every dollar of earnings. Another useful way to look at this: Turn the P/E ratio around to look at the E/P ratio, which when expressed as a percentage gives us the earnings yield. For instance: 1/15 gives us an earnings yield of 6.67%.

While we have already looked at Biogen Inc beta and P/E ratio, the EPS cannot be ignored. Biogen Inc EPS for the trailing twelve months was 15.24. Traders and investors often use earnings per share (TTM) to determine a company’s profitability for the past year. So in essence, EPS is the amount of a company’s net income per share of common stock. Earnings per share equal the company’s net income less any dividends paid on preferred stock divided by the weighted average number of common stock shares outstanding during the year. Biogen Inc is estimated to release its next earnings report on 12 / 2017 (N/A-Not know at this time). It would be interesting to see how the earnings fair out considering the recent developments.

The Analyst Chirp:

Biogen Inc. (BIIB) has received an average target price from analysts of $352.87 amounting to a recommendation rating of Overweight. That comes from 35 different analysts. Perhaps, the driver for that assessment comes from the company’s valuations. Right now, we are looking at a median price-to-earnings ratio for this calendar year of 14.07. To give a sense of trend, the same data point on the estimate for next year is currently sitting at 13.18 times earnings. Drilling down a bit further, this quarter, we are looking at an average estimate from analysts for earnings per share level of 29.00. That shift to 13.00 heading into next quarter.

 

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Continue Reading

 


Lithium Stocks

 

Trending